March 3, 2009) – Thrasos Therapeutics, Inc., a biotechnology company developing unique therapeutic agents to treat severe organ failure and other critical medical needs, announced today the issuance of U.S. patent number 7,482,329 covering a proprietary set of small molecules that selectively activate key receptors of the bone morphogenetic protein (BMP) family.
The details can be read here.
No comments:
Post a Comment